RxDoctor Payments Data

Dushyant Gandhi, MD

Cardiovascular Disease · Vernon, CTNPI 1689683138

Payments from drug & device makers

$3,108in general payments, 2019–2025

Across 157 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Pfizer$379
  • E.r. Squibb & Sons, L.L.C.$343
  • AstraZeneca$329
  • Novartis$199
  • Boehringer Ingelheim$195
  • plus $298 from 5 others

What the payments were for

  • Food & beverage$3,00297%
  • Education$1063%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson69$1,364
Pfizer19$379
E.r. Squibb & Sons, L.L.C.17$343
AstraZeneca14$329
Novartis10$199
Boehringer Ingelheim11$195
Amgen9$153
Merck4$78
Kowa Pharmaceuticals America, Inc.2$28
GSK1$23
Bardy Diagnostics, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,108 in reported general payments places this provider in the 60th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$190,992
Medicare patients
978
Services billed
2,504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban398$408,951
XareltoRivaroxaban260$310,319
EntrestoSacubitril/Valsartan108$142,826
JardianceEmpagliflozin27$26,046
FarxigaDapagliflozin Propanediol20$20,342
Repatha SureclickEvolocumab24$17,657
BrilintaTicagrelor15$13,686
Metoprolol Succinate827$10,552
Atorvastatin Calcium647$5,293
Diltiazem 24hr Er (Cd)Diltiazem Hcl169$4,143
Nebivolol Hcl65$4,056
Digoxin97$3,637
Ranolazine ErRanolazine18$2,307
Ezetimibe99$2,248
Metoprolol Tartrate269$1,889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$379$408,951398 claims
Johnson & JohnsonXarelto$1,364$310,319260 claims
NovartisEntresto$199$142,826108 claims
AstraZenecaFarxiga, Brilinta$329$34,02835 claims
Boehringer IngelheimJardiance$195$26,04627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Vernon

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →